Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025Breast Cancer Basic and Clinical ResearchOpen Access

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2− Early Breast Cancer in the Real-World Setting

View Full Paper
Ask AI
Bookmark
Share

Authors

KGKaren GambaroKRKahina RachediMBMark BasikJewish General Hospital

Discussion

Loading...

Member takes

Implication

Retrospective cohort study analyzes outcomes in HR+/HER2− breast cancer patients, revealing high recurrence rates despite neoadjuvant and adjuvant therapy.

Key Points

  • Recurrence rates reached 58.4% after 10 years for patients treated with adjuvant ET.
  • 75.6% of patients received adjuvant ET, with significant preference for combination therapies.
  • Retrospective longitudinal cohort study involved 541 patients from a Canadian cancer registry.
  • High unmet need for effective treatments highlights the urgency of addressing disease recurrence.

Cite This Study

Gambaro et al. (2025) studied this question.

synapsesocial.com/papers/6930dc9eea1aef094cca2d8fhttps://doi.org/10.1177/11782234251395892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives2023 · 224 citations